ClinicalTrials.gg
RecruitingNCT07005752Updated Jul 29, 2026

A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).

A Phase 4 interventional study of CnU cap. 250mg & Ursa placebo tab. 200mg and Ursa tab. 200mg & CnU placebo cap. 250mg in Cholesterol Cholelithiasis, sponsored by Myungmoon Pharma. Co. Ltd.. Recruiting at 13 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Myungmoon Pharma. Co. Ltd. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 750 mg administration in patients with Cholesterol gallstone (radiolucent gallstones)

02

Conditions studied

  • Cholesterol Cholelithiasis

Browse trials for

Keywords

  • Cholesterol gallstone
03

In context

Cholelithiasis

192 studies on the registry are indexed under Cholelithiasis; 44 are open to participants now.

This study's planned enrollment of 484 is above the median of 90 across 135 interventional studies indexed under Cholelithiasis.

Browse Cholelithiasis studies →

Lead sponsor

Myungmoon Pharma. Co. Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals who have voluntarily agreed to participate in this clinical trial
  2. Adults aged 19 years and older
  3. Individuals diagnosed with gall bladder stone(GB stone) with a maximum diameter size of 15 mm or less, as determined by abdominal ultrasonography at the screening stage, and who have radiolucent GB stones on plain abdominal X-ray

Exclusion criteria

Exclusion Criteria:

1. Medical History

  1. Patients with frequent biliary colic or biliary infections (severe pancreatic changes, such as ileal resection, resection surgery, or partial ileitis, may alter the composition of bile acids circulating in the intestines).
  2. Patients with obstructive jaundice.
  3. Patients with liver disease.
  4. Patients with severe kidney disease.
  5. Patients with severe biliary obstruction (due to choleretic effects, symptoms may worsen).
  6. Patients with underlying diseases that could worsen biliary obstruction (such as biliary cancer, cholangitis, or biliary cysts).
  7. Patients with acute cholecystitis.
  8. Patients with peptic ulcers (due to mucosal irritation, symptoms may worsen).
  9. Patients with inflammatory bowel diseases, such as Crohn's disease.
  10. Patients with cholestasis.
  11. Patients with abnormal gallbladder contraction.
  12. Individuals with a history of malignant tumors within 5 years prior to the screening stage.
  13. Individuals with a history of gastrointestinal surgery.
  14. Individuals known to have to the ingredients or additives of the clinical trial drug.
  15. Individuals showing disorders in the cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous systems, or individuals who have had or currently have a mental disorder that could significantly affect this clinical trial.
  16. Individuals with drug or alcohol addiction.
  17. Individuals with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Individuals showing abnormal test results at the screening stage:

  1. ≥ 35 kg/m².
  2. or AST > 2.0 x .
  3. Total > 2.0 x ULN.
  4. \< 60 mL/min/1.73 m² (CKD-EPI formula).
  5. Positive results in serum tests (, Ab, Ab, Syphilis reagin test).

3. drugs and therapies

The following drugs may be used after a and registration:

  1. Medications that increase bile secretion within 1 week prior to screening (e.g., estrogen, hormonal , some lipid-lowering agents), or medications that reduce blood cholesterol (e.g., clofibrate).
  2. Medications containing cholestyramine, colestipol, activated charcoal, magnesium, or aluminum hydroxide antacids within 2 weeks prior to screening.
  3. Oral bile acid dissolution agents within 4 weeks prior to screening (e.g., chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), HMG-CoA reductase inhibitors, Terpene).
  4. Oral anti-diabetic medications (e.g., tolbutamide).
  5. Individuals who have received bile acid treatment within 4 weeks prior to screening.

The following drugs cannot be used regardless of the washout period: Alpha-methyldopa.

4. Pregnant and breastfeeding women

5. Contraception

Participants and their spouses (or partners) who do not use medically acceptable contraceptive methods throughout the clinical trial period:

  1. Use of intrauterine devices (IUD) or intrauterine systems (IUS) with proven failure rates of pregnancy.
  2. Use of dual barrier contraception (male condom and cervical cap: contraceptive vaginal diaphragm or cervical cap) combined with spermicides.
  3. Sterilization procedures (vasectomy, tubal ligation or cauterization, hysterectomy).

6. Other individuals deemed inappropriate for participation in the clinical trial by the investigator.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
484 participants (estimated)

Study arms

  • Experimental
    CnU capsule 250 mg(1 capsule) and Ursa placebo tablet 200 mg(1 tablet)

    Drug: CnU cap. 250mg & Ursa placebo tab. 200mg

  • Active comparator
    Ursa tablet 200 mg(1 tablet) and CnU placebo capsule 250 mg(1 capsule)

    Drug: Ursa tab. 200mg & CnU placebo cap. 250mg

Interventions

  • DrugCnU cap. 250mg & Ursa placebo tab. 200mg

    CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

  • DrugUrsa tab. 200mg & CnU placebo cap. 250mg

    Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

06

What researchers measure

Primary outcomes

  1. Response to dissolution therapy

    Response to dissolution therapy at 24 weeks compared to baseline in patients with Cholesterol gallstones. The dissolution response rate is defined as the sum of the GB stones complete and partial dissolution rates.

    Time frame: From baseline to the end of treatment at 24 weeks

Secondary outcomes

  1. 1) GB stones complete dissolution rate 2) GB stones partial dissolution rate 3) GB stones dissolution rate

    1. GB stones complete dissolution rate: The complete GB stones dissolution rate is defined as the proportion of subjects with no detectable gallbladder stones on ultrasonography. 2. GB stones partial dissolution rate: The partial GB stones dissolution rate is defined as the proportion of subjects who show a reduction of more than 50% in GB stones volume. 3. GB stones dissolution rate: The GB stones dissolution rates are defined as the rate of reduction in GB stones volume and the area of gallbladder sludge as measured by ultrasonography.

    Time frame: From baseline to the end of treatment at 24 weeks

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Nov 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
Jun 5, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Nov 10, 2027
CompletionEst.
Jun 13, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07005752
Lead sponsor
Myungmoon Pharma. Co. Ltd.
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Jul 28, 2025
Primary completion
Nov 10, 2027 (estimated)
Completion
Jun 13, 2028 (estimated)
Last update
Jul 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion